Physician profile
David N Barrera
NPI 1063444297
$16,047.23
in general payments reported to CMS, 2019-2025
68 companies · $2,556 in 2025
The $2,556 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,521 · 2020: $1,536 · 2021: $1,645 · 2022: $1,883 · 2023: $1,895 · 2024: $4,010 · 2025: $2,556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,127 · Long Term Medical Supply Or Device Loan: $2,115 · Consulting Fee: $1,138 · Education: $82.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,126.56 |
| Long Term Medical Supply Or Device Loan | $2,114.51 |
| Consulting Fee | $1,137.50 |
| Education | $82.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,469.66 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,696.59 | 2019-2025 | Enhertu, Calquence, Imfinzi |
| Pfizer INC. | $935.24 | 2019-2025 | |
| Amgen INC. | $901.17 | 2019-2022 | |
| Janssen Biotech, INC. | $816.11 | 2019-2025 | Erleada, Darzalex, Talvey |
| Takeda Pharmaceuticals U.S.A., INC. | $540.40 | 2019-2025 | Fruzaqla, Iclusig |
| Merck Sharp & Dohme LLC | $507.27 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $505.94 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Incyte Corporation | $489.75 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Astellas Pharma US INC | $459.29 | 2019-2025 | Xtandi |
| E.R. Squibb & Sons, L.L.C. | $450.64 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Seagen INC. | $379.88 | 2019-2023 | Adcetris |
| Sobi, INC | $347.73 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $312.36 | 2019-2022 | |
| Genentech USA, INC. | $303.14 | 2019-2024 | Tecentriq, Venclexta, Tecentriq Hybreza |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Barrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.